Study Finds Fatigue and Physical Health Measures Best Reflect Changes in Lupus Over Time

A new pooled analysis of adults with systemic lupus erythematosus (SLE) found commonly used patient-reported measures varied meaningfully in sensitivity to clinical changes in SLE, disease course and follow-up timing. Lupus disease complexity and variability makes accurate measurement of disease activity very challenging. Measurement of disease activity in lupus is central to clinical research and clinical trials for classifying and monitoring groups of patients and gauging responses to a new drug. Patient-reported measures can capture symptoms such as fatigue, pain, and physical limitations that clinician-assessed tools often under-recognize, but how well they detect meaningful change across different disease courses has not been well defined. 

Researchers analyzed data of 1,908 people with SLE who received belimumab in two Phase 3 trials (BLISS-52 and BLISS-76) and completed a variety of self-reported questionnaires, including the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F), a patient questionnaire that assesses fatigue and how its impact on daily activities; the Physical Component Summary score of the 36-Item Short Form Health Survey (SF-36), a widely used patient-reported measure of physical health-related quality of life; and the EQ-5D-3L,  a standardized, general measure of health-related quality of life used across different patient populations and clinical settings. Participants were assessed using visit-specific follow-up through week 52. The researchers found that how well patient-reported measures detected change depended on patients’ disease patterns and follow-up timing. FACIT-F and SF-36 PCS were the most consistent measures, especially among patients who improved. EQ-5D-3L showed smaller and less consistent changes, although it met meaningful-change thresholds in some comparisons.  

The findings suggest that measures focused on fatigue and physical health may help researchers better capture the benefits of lupus treatments. They highlight the limits of generic tools for measuring treatment benefit in SLE and suggest that using the EQ-5D-3L alone may underestimate benefits that people with SLE value, especially less fatigue and better physical function. Measures such as FACIT-F and SF-36 PCS can provide useful additional information. Future research should examine whether patient-reported measures, alone or combined with clinician assessments, better capture meaningful benefits of lupus treatments over time. Learn more about participating in clinical trials.

Read the study